Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
Volume: 88, Issue: 1, Pages: 29 - 39
Published: Jul 9, 2022
Paper Details
Title
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
Published Date
Jul 9, 2022
Volume
88
Issue
1
Pages
29 - 39
Notes
History